ライフサイエンスコーパス: release factor

1 UPF1, SMG1 kinase, SMG8, SMG9 and eukaryotic release factors).

2 retains its normal function as a translation release factor.

3 imited by truncation due to competition with release factors.

4 ensuring termination with either of the two release factors.

5 atically inhibit rates of peptide release by release factors.

6 ome, facilitates the dissociation of class I release factors.

7 y of four putative mitochondrial translation release factors.

8 12 N terminus functions to bind host vesicle release factors.

9 mone 44 (DH44), an ortholog of corticotropin-releasing factor.

10 alize with the stress hormone, corticotropin releasing factor.

11 ease factor complex that includes eukaryotic release factor 1 (eRF1) and eRF3.

12 saturating and limiting levels of eukaryotic release factor 1 (eRF1).

13 he interaction between MoMLV RT and peptidyl release factor 1 (eRF1).

14 ized by two similar class 1 release factors, release factor 1 (RF1) and release factor 2 (RF2).

15 3.1-A crystal structure of Escherichia coli release factor 1 (RF1) bound to the 70S ribosome in resp

16 acids (nnAAs) is limited by competition with release factor 1 (RF1).

17 UAA codons, which permitted the deletion of release factor 1 and reassignment of UAG translation fun

18 Deletion of release factor 1 in Escherichia coli enhances translatio

19 cherichia coli that lacks all TAG codons and release factor 1, endowing this organism with the orthog

20 Interestingly, the release factor 1-specific codon TAG maintains a more or

21 s any endogenous in-frame UAGN sequences and release factor 1.

22 hrough by silencing expression of eukaryotic release factors 1 and 3 (eRF1 and eRF3) or by introducin

23 de), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (antalarmin), and a

24 ne domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to develop improved

25 Ablation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of R

26 n of Ras protein-specific guanine nucleotide releasing factor 1 (RasGrf1), a Ras activator (5-fold, P

27 with Ras protein-specific guanine nucleotide-releasing factor 1 (RASGRF1), leading to impaired activa

28 armacologic inhibition (with a corticotropin-releasing factor 1 receptor antagonist) of pain-related

29 s to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagonist-reversible

30 utations in the prfB and prfC genes encoding release factor 2 (RF2) and RF3 that restore the wild typ

31 don in the A site by specifically recruiting release factor 2 (RF2), initially in a compact preaccomm

32 eases tmRNA activity on ribosomes undergoing release factor 2 (RF2)-mediated termination at UGA stop

33 release factors, release factor 1 (RF1) and release factor 2 (RF2).

34 We report the crystal structure of release factor 2 bound to ribosome with an aminoacyl tRN

35 peptide release, packs with the GGQ motif in release factor 2.

36 26907 in the ras-specific guanine-nucleotide releasing factor 2 (RASGRF2) gene, encoding a protein th

37 e processes; Ras-specific guanine nucleotide releasing factor 2 (RasGRF2).

38 ene (Ras protein-specific guanine nucleotide-releasing factor 2) with all clinical events except stro

39 Eukaryotic peptide release factor 3 (eRF3) is a conserved, essential gene i

40 o sterically occlude the binding of peptidyl release factor 3 (eRF3) to eRF1.

41 Release factor 3 (RF3) is a GTPase found in a broad rang

42 Normally, during termination, the class 2 release factor 3 (RF3), a GTPase, functions downstream o

43 Protein release factor 3 (RF3), a guanosine triphosphatase, bind

44 nslation initiation factor 4G and eukaryotic release factor 3a (eRF3a).

45 After considering the releasing factor (66.6%) from the swab, the final accura

46 Corticotropin-releasing factor, a stress-related neuropeptide implicat

47 re termination, including the stimulation of release factor activity and the dissociation and recycli

48 ated by PTRF (polymerase I transcription and release factor, also known as cavin-1), which has previo

49 es a network of interactions between the two release factors and the ribosome.

50 trongly inhibits peptidyl-tRNA hydrolysis by release factors and, to a lesser extent, peptide bond fo

51 ess neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of

52 ing by increased expression of corticotropin-releasing factor and its feedback regulation of TLR4 exp

53 cal function in termination, both classes of release factor are also involved in a post peptidyl tran

54 (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol drinking duri

55 ion because they have one of the alternative release factors, ArfA or ArfB.

56 ent of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tum

57 ression of PTRF (polymerase I and transcript release factor) associated selectively with their glucos

58 RAD and suggest that positioning this client-release factor at the retrotranslocation site may afford

59 Corticotropin releasing factor binding protein (CRF-BP) was originally

60 ed Crk SH3 domain-binding guanine-nucleotide releasing factor (C3G) binding to CrkII, whereas inhibit

61 Infusion of hypothalamic-releasing factors can reactivate the thyroid axis in pat

62 nd asked whether SSc-injured epidermal cells release factors capable of promoting fibrosis.

63 ound that the availability of the functional release factor complex Sup45-Sup35 strongly influences t

64 c translational termination is mediated by a release factor complex that includes eukaryotic release

65 othalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus o

66 os activation were observed in corticotropin releasing factor-containing neurons of the paraventricul

67 nical termination on stop codons, eukaryotic release factors contribute to cotranslational protein qu

68 BDNF signaling is mediated by corticotrophin-releasing factor (CRF) acting in the NAc.

69 We report that corticotropin-releasing factor (CRF) acts in the ventral tegmental are

70 gh it has long been known that corticotropin-releasing factor (CRF) and CRF receptors are prominent i

71 ion between the stress hormone corticotropin releasing factor (CRF) and glutamate release onto dopami

72 d to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-releasing horm

73 The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (CRF-R1, CRF-R2

74 Corticotropin-releasing factor (CRF) and nociceptin/orphanin FQ (nocic

75 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegme

76 e report the identification of corticotropin-releasing factor (CRF) as a critical component of the ca

77 To investigate corticotropin-releasing factor (CRF) contributions to fear memory in L

78 Corticotropin releasing factor (CRF) coordinates the brains responses

79 the central extrahypothalamic corticotropin-releasing factor (CRF) expression is associated with str

80 enced by the highly conserved corticotrophin-releasing factor (CRF) family of peptides and receptors

81 The corticotropin-releasing factor (CRF) family of peptides includes CRF a

82 tin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with high affinity

83 n of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated in these diso

84 levant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a circadian out

85 e self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in the paraventricu

86 k indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological responses asso

87 ole of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced binge eating in

88 work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during craving and rela

89 ibution of the stress hormone, corticotropin-releasing factor (CRF) in the mouse brain.

90 tly described the existence of corticotropin-releasing factor (CRF) in the mouse cochlea.

91 thasone (DEX) inhibition, and corticotrophin-releasing factor (CRF) induced activation.

92 ggests that catecholamines and corticotropin-releasing factor (CRF) interact in a serial manner to ac

93 Corticotropin-releasing factor (CRF) is an important link between stre

94 Corticotropin-releasing factor (CRF) is critical for the endocrine, au

95 emonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neurons that inne

96 Corticotropin-releasing factor (CRF) is expressed in the Ce, has a rol

97 Corticotropin releasing factor (CRF) is the primary mediator of stress

98 Corticotropin-releasing factor (CRF) mediates anxiogenic responses by

99 Corticotrophin-releasing factor (CRF) modulates the influence of stress

100 Corticotropin-releasing factor (CRF) mRNA expression in the hypothalam

101 on, potentially by activating corticotrophin releasing factor (CRF) neurons in the anterolateral cell

102 d activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed nucleus of the

103 pecifically recruited GABA and corticotropin-releasing factor (CRF) neurons in the mPFC and produced

104 hip between corticosterone and corticotropin-releasing factor (CRF) on both beta-amyloid (Abeta) and

105 of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabsorption and the

106 ry but did not increase either corticotropin-releasing factor (CRF) or corticosterone.

107 Corticotropin-releasing factor (CRF) orchestrates the stress response,

108 The corticotropin-releasing factor (CRF) peptide hormone family members co

109 derable evidence suggests that corticotropin-releasing factor (CRF) plays an important role in regula

110 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1) is a target fo

111 eta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intac

112 awal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expression and signall

113 Corticotropin-releasing factor (CRF) receptors are found in stress-rel

114 Because corticotropin-releasing factor (CRF) receptors are implicated, we comp

115 Corticotropin-releasing factor (CRF) receptors-which bind the hormone

116 Corticotropin releasing factor (CRF) regulates physiological and behav

117 e stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsal raphe nucleu

118 e through alterations in brain corticotropin-releasing factor (CRF) regulation of neurocircuitry invo

119 Corticotropin-releasing factor (CRF) signaling at the CRF1 receptor (C

120 Alterations in corticotropin-releasing factor (CRF) signaling pathways have been impl

121 VN) have been shown to inhibit corticotropin releasing factor (CRF) synthesis via GABA(A) receptors.

122 H secretion by activating the corticotrophin-releasing factor (CRF) system and sympathoadrenal pathwa

123 The corticotropin releasing factor (CRF) system in the central amygdala (C

124 The corticotropin releasing factor (CRF) system in the central amygdala (C

125 The corticotropin-releasing factor (CRF) system, which is involved in stre

126 gdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypothalamic-pituitar

127 The corticotropin-releasing factor (CRF) type 1 receptor (CRF1R) for the 4

128 Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (CRFR1s) reduces

129 Corticotropin releasing factor (CRF) within the ventral tegmental area

130 We investigated how corticotrophin releasing factor (CRF), a critical stress response media

131 Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in respo

132 e number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide that has a promin

133 ited different sensitivity to corticotrophin-releasing factor (CRF), a stress hormone that has been i

134 this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modulator of stress

135 opeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor, Dh44R1.

136 The neuroactive substances corticotropin-releasing factor (CRF), arginine-vasopressin (AVP), hist

137 is thought to communicate via corticotropin-releasing factor (CRF), but studies have yet to examine

138 The neuropeptide, corticotropin-releasing factor (CRF), coordinates the physiological an

139 es indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dopamine, glutama

140 Corticotropin-releasing factor (CRF), originally characterized as the

141 Corticotropin-releasing factor (CRF), the major stress peptide in the

142 e focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator of the stress r

143 Corticotropin-releasing factor (CRF), the stress-related neuropeptide,

144 oradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism] that regulat

145 nd inhibitory transmission in corticotrophin-releasing factor (CRF)-expressing dorsal-medial (mpd) ne

146 en shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase in tonic locus

147 Corticotropin-releasing factor (CRF)-mediated mechanisms in the bed nu

148 tin 1 (Ucn 1) is an endogenous corticotropin releasing factor (CRF)-related peptide.

149 the stress-sensitive peptide, corticotropin releasing factor (CRF).

150 ocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).

151 opaminergic neurons expressing corticotropin-releasing factor (CRF).

152 e prototypical stress hormone, corticotropin releasing factor (CRF).

153 e stress-related neuropeptide, corticotropin-releasing factor (CRF).

154 the anxiogenic neuromodulator, corticotropin releasing factor (CRF).

155 that produce the neuropeptide corticotropin-releasing factor (CRF).

156 uding neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).

157 The mammalian corticotropin releasing factor (CRF)/urocortin (Ucn) peptide hormones

158 tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK561679 differentia

159 T proteins function mechanistically as pause-release factors critical to expression of genes that are

160 sult in a tangible model disclosing how hPSC-released factors deflect CHIR99021-induced lineage commi

161 ide and promotes dissociation of the class I release factors during the termination of protein synthe

162 iated with mRNA, P-site deacylated tRNA, and release factor eRF1 and must be recycled by dissociating

163 top codons UAA, UAG or UGA by the eukaryotic release factor eRF1.

164 ly on an evolutionarily unrelated omnipotent release factor (eRF1) to recognize all three stop codons

165 functional interplay between two eukaryotic release factors, eRF1 and eRF3, and the ribosome, in whi

166 the complex functional interplay between two release factors, eRF1 and eRF3, in which GTP hydrolysis

167 cy of competition for the stop codon between release factors (eRFs) and near-cognate tRNAs is largely

168 ion of SMG1 and UPF1 with the two eukaryotic release factors (eRFs) during SURF complex formation at

169 transcriptionally activated in corticotropin releasing factor-expressing cells.

170 region-specific alterations of corticotropin-releasing factor expression and promoter methylation, ch

171 neuropeptides vasopressin and corticotropin-releasing factor facilitate, while serotonin inhibits, a

172 rs, which bind peptides of the corticotropin releasing factor family and are key mediators in the str

173 NGF and the hormone urotensin (corticotropin-releasing factor family ligand).

174 ADP release factors for DEAD-box proteins have not been repo

175 RasGRP1, a guanine nucleotide-releasing factor for Ras, plays an important role in pos

176 purified and found to be Galpha subunit GDP release factor/GEFs.

177 Further, mutations in the release factor gene can result in a premature stop codon

178 al. provide a causal link between histamine-releasing factor (HRF) interactions with IgE and food al

179 lacks a secreted factor related to histamine-releasing factor (HRF).

180 Histamine-releasing factor (HRF; also known as translationally con

181 ther suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-adrenal axis sys

182 discovered that UPF3B (i) interacts with the release factors, (ii) delays translation termination and

183 thropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in the paraventric

184 ned in vitro system, we explored the role of release factors in canonical termination and post PT QC.

185 l axis, including signaling by corticotropin-releasing factor, in the pathophysiology of PTSD.

186 A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen

187 Corticotropin-releasing factor infusions into LA impair the consolidat

188 Corticotropin-releasing factor infusions into the central nucleus of t

189 In preeclampsia, the placenta releases factors into the maternal circulation that caus

190 While corticotrophin releasing factor is the prototypic member of this class,

191 in bacteria, but coupled stages of the same release-factor mediated process.

192 p codons, suggesting a general mechanism for release-factor-mediated translational termination in whi

193 cting to vasopressinergic and corticotrophin releasing factor neurons in the paraventricular nucleus,

194 acts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine, and serotoni

195 e cell, thereby establishing its function as release factor of mislocalized palmitoylated proteins in

196 l impact of treatment with such hypothalamic releasing factors on recovery from critical illness as w

197 ess of the way PoTC was prepared with either release factors or puromycin.

198 ss of Upf (up-frameshift) factors, defective release factors, or the presence of the aminoglycoside g

199 ior hypothalamus that may gate corticotropin-releasing factor output from the amygdala to the anterio

200 pluripotency genes by dissociating the pause release factor P-TEFb from an inactive complex containin

201 Active transcription starts when the pause release factor P-TEFb is recruited to initiate productiv

202 Cohesin dynamics are controlled by the releasing factors Pds5 and Wapl and the cohesin stabiliz

203 ed competition between ternary complexes and release factors perturbs the UGA readthrough level.

204 appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B, and glucose tr

205 Release of the completed protein requires a release factor protein acting at the termination/stop co

206 The eukaryotic release factor protein family has also been dramatically

207 re stop codon and production of the complete release factor protein.

208 These release factor proteins are involved in the termination

209 involved in the translation and synthesis of release factor proteins, which has been observed in diff

210 Similarly, polymerase I transcript release factor (PTRF) deficiency resulted in decreased i

211 Polymerase I and transcript release factor (PTRF) is a protein highly expressed in a

212 e we report that polymerase I and transcript release factor (PTRF), a gene known to regulate caveolae

213 caveolar protein, polymerase1 and transcript release factor (Ptrf).

214 f caveolin-1 and polymerase I and transcript release factor (PTRF)/cavin-1 correlated closely in a pa

215 Polymerase I and transcript release factor (PTRF)/cavin-1 is a structural protein co

216 ssory factors (e.g., polymerase I transcript release factor [PTRF] or Supt5H).

217 logical consequence of central corticotropin-releasing factor receptor (CRF-R) activation.

218 ed differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 in acute stress

219 haracterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antagonist, GW87600

220 (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-dependent mechanism

221 g the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor) antagonist i

222 Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppresses stress-ind

223 member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).

224 what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97 expression is

225 r-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable exceptions.

226 ed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the amygdala of m

227 constitutive activation of the corticotropin-releasing factor receptor family homologue SEB-3.

228 ent study examines the role of corticotropin releasing factor receptor subtypes 1 and 2 (CRFR1, CRFR2

229 CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R) possessing a

230 vestigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1) could prevent

231 ctions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) potentiation of

232 re the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) and its native

233 ed interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptid

234 Corticotropin-releasing factor receptor type 1 (CRFR1) is involved in

235 compartments, we show that the corticotropin-releasing factor receptor type 1 has a specific monomer/

236 nsmembrane domain of the human corticotropin-releasing factor receptor type 1 in complex with the sma

237 The corticotropin-releasing factor receptor type 1 is a class B receptor w

238 librium is established for the corticotropin-releasing factor receptor type 1.

239 Corticotropin-releasing factor receptor type 2 (CRFR2) has been implic

240 central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) has been sugges

241 bserved abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) to be associate

242 The corticotropin-releasing factor receptor type 2a (CRF(2(a))R) possesses

243 Corticotropin-releasing factor receptor-1 (CRF(1)) mediates the stress

244 is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but i

245 tention were attenuated by the corticotropin-releasing factor receptor-1 antagonist antalarmin but no

246 Corticotropin-Releasing Factor Receptors (CRFRs) are class B1 G-protei

247 Corticotropin-releasing factor receptors (CRFRs), class B G protein-co

248 Codon selection, releasing factor recognition sequence and specific intro

249 Release factors recognize stop codons in the ribosomal A

250 Urocortin 3 (Ucn 3) is a corticotrophin-releasing factor related neuropeptide highly expressed i

251 codons are recognized by two similar class 1 release factors, release factor 1 (RF1) and release fact

252 tructure of a termination complex containing release factor RF1 bound to the 70S ribosome in response

253 s of recognition of all three stop codons by release factors RF1 and RF2 can now be described.

254 steady state amount of mRNA and protein for release factors RF1 and RF2 during exponential growth.

255 ion-like protein (RepA-WH1) into the E. coli releasing factor RF1 promotes its aggregation and enable

256 Stop codons are recognized by class I release factors (RF1 and RF2 in Escherichia coli), which

257 ation by facilitating the removal of class 1 release factors (RF1 and RF2) from the ribosome followin

258 ecognizes stalled ribosomes and recruits the release factor RF2, which catalyses the termination of p

259 mes stalled on truncated mRNAs by recruiting release factor RF2, which normally binds stop codons to

260 cal for UGA codon recognition by the class 1 release factor RF2.

261 tion in Bacteria and Archaea is initiated by release factors (RFs) 1 or 2 recognizing a stop codon in

262 of the specificity of the bacterial class I release factors (RFs) in decoding stop codons has evolve

263 s of ribosome complexes with bound tRNAs and release factors show considerable contacts between these

264 Alterations in central corticotropin-releasing factor signaling pathways have been implicated

265 In addition to this strain release factor, steric and inductive effects contribute

266 forces and an inflammatory microenvironment release factors such as a disintegrin and metalloprotein

267 n-gamma (IFN-gamma) and induce cytolysis via releasing factors such as perforin, which permeabilizes

268 Moreover, Tia1/Pub1 acts cooperatively with release factor Sup35/eRF3 to establish a two-protein sel

269 Here, we examined how the canonical release factors Sup45-Sup35 (eRF1-eRF3) and their paralo

270 s), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intestinal response

271 s probed using a dexamethasone/corticotropin-releasing factor test.

272 de the kinase domain constitute a nucleotide release factor that likely interacts with the small lobe

273 conserved histidine in all bacterial class I release factors that forms a stacking interaction with t

274 For example, apoptotic cells can release factors that influence the proliferation and sur

275 jor differentially activate keratinocytes to release factors that limit infection in monocytes.

276 fibroblasts overexpress matrix proteins and release factors that promote further recruitment of acti

277 w that mast cells sense colder temperatures, release factors that promote UCP1 expression, and are an

278 p53-expressing senescent stellate cells release factors that skew macrophage polarization toward

279 The TNFalpha-activated PAEC released factors that induce huTreg chemotaxis, partiall

280 ontrol of the pathogen, but B. dendrobatidis releases factors that inhibit in vitro and in vivo lymph

281 role in maintaining vascular homeostasis by releasing factors that regulate local blood flow, system

282 counteracting the functions of corticotropin-releasing factor, the primary stress-mediating neuropept

283 lin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing hormone and calc

284 During normal translation, the binding of a release factor to one of the three stop codons (UGA, UAA

285 rolysis for its activity and requires an ADP release factor to reset its ATPase cycle.

286 buting ions, removing neurotransmitters, and releasing factors to influence blood flow and neuronal a

287 Corticotropin releasing factor type 1 (CRF1) is a key component in the

288 Activation of corticotropin-releasing factor type 1 (CRF1) receptors in the CeA play

289 ve effect is mediated via the corticotrophin-releasing factor type 1 receptor (CRF1R, also known as C

290 peated social stress decreased corticotropin-releasing factor type 1 receptor and increased mu-opioid

291 We found that corticotropin-releasing factor type 1 receptor within the paraventricu

292 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

293 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

294 The corticotropin-releasing factor type 2 receptor (CRFR2) is suggested to

295 hat the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP elevation, and ac

296 The natural cell type(s) that synthesize and release factor VIII (FVIII) into the circulation are sti

297 ion of diverse microbial moieties, including released factors, which modulate host immune responses t

298 ombined administration of those hypothalamic releasing factors, which have been identified as suppres

299 complexes on DNA by antagonizing the cohesin release factor Wings-apart like protein (Wapl).

300 cteria decode stop codons using two separate release factors with differing specificities for the sec